Literature DB >> 25245387

TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process.

Lavannya M Pandit1, Eric E Lloyd2, Julia O Reynolds2, William S Lawrence2, Corey Reynolds2, Xander H T Wehrens2, Robert M Bryan2.   

Abstract

TWIK-2 (KCNK6) is a member of the 2-pore domain (K2P) family of potassium channels, which are highly expressed in the vascular system. We tested the hypothesis that TWIK-2 deficiency leads to pulmonary hypertension. TWIK-2 knockout mice and their wildtype littermates at 8 weeks of age had similar mean right ventricular systolic pressures (24±3 and 21±3 mm Hg, respectively.) Significantly, by 20 weeks of age, the mean right ventricular systolic pressures in TWIK-2 knockout mice increased to 35±3 mm Hg (P≤0.036), whereas mean right ventricular systolic pressures in wildtype littermates remained at 22±3 mm Hg. Elevated mean right ventricular systolic pressures in the TWIK-2 knockout mice was accompanied by pulmonary vascular remodeling as determined by a 25% increase in the cross-sectional area of the vessels occupied by the vessel wall. Additionally, secondary branches of the pulmonary artery from 20-week-old TWIK-2 knockout mice showed an enhanced contractile response to U46619 (10(-6) moles/L), a thromboxane A2 mimetic, which was completely abolished with the Rho-kinase inhibitor, Y27632 (10(-6) and 10(-5) moles/L). Treatment of TWIK-2 knockout mice with the Rho-kinase inhibitor, fasudil, in the drinking water for 12 weeks, abolished the development of pulmonary hypertension and attenuated the vessel remodeling. We concluded that mice deficient in the TWIK-2 channel develop pulmonary hypertension between 8 and 20 weeks of age through a mechanism involving Rho-kinase. Our results suggest that downregulation of TWIK-2 in the pulmonary vasculature may be an underlying mechanism in the development of pulmonary hypertension.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  KCNK6; Rho-kinase; TWIK-2; potassium channel; pulmonary hypertension

Mesh:

Substances:

Year:  2014        PMID: 25245387      PMCID: PMC4231005          DOI: 10.1161/HYPERTENSIONAHA.114.03406

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  41 in total

Review 1.  The role of the right ventricle in pulmonary arterial hypertension.

Authors:  A Vonk Noordegraaf; N Galiè
Journal:  Eur Respir Rev       Date:  2011-12

2.  The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally.

Authors:  Edwina Cahill; Simon C Rowan; Michelle Sands; Mark Banahan; Donal Ryan; Katherine Howell; Paul McLoughlin
Journal:  Exp Physiol       Date:  2012-02-24       Impact factor: 2.969

Review 3.  New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling.

Authors:  Frank K Kuhr; Kimberly A Smith; Michael Y Song; Irena Levitan; Jason X-J Yuan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-13       Impact factor: 4.733

Review 4.  Updated clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

5.  Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery.

Authors:  A D Medhurst; G Rennie; C G Chapman; H Meadows; M D Duckworth; R E Kelsell; I I Gloger; M N Pangalos
Journal:  Brain Res Mol Brain Res       Date:  2001-01-31

6.  A novel channelopathy in pulmonary arterial hypertension.

Authors:  Lijiang Ma; Danilo Roman-Campos; Eric D Austin; Mélanie Eyries; Kevin S Sampson; Florent Soubrier; Marine Germain; David-Alexandre Trégouët; Alain Borczuk; Erika Berman Rosenzweig; Barbara Girerd; David Montani; Marc Humbert; James E Loyd; Robert S Kass; Wendy K Chung
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

Review 7.  Rho-kinase: important new therapeutic target in cardiovascular diseases.

Authors:  Kimio Satoh; Yoshihiro Fukumoto; Hiroaki Shimokawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-27       Impact factor: 4.733

8.  TWIK-2, an inactivating 2P domain K+ channel.

Authors:  A J Patel; F Maingret; V Magnone; M Fosset; M Lazdunski; E Honoré
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

9.  Alterations of N-3 polyunsaturated fatty acid-activated K2P channels in hypoxia-induced pulmonary hypertension.

Authors:  Gorm Nielsen; Christine Wandall-Frostholm; Veeranjaneyulu Sadda; Aida Oliván-Viguera; Eric E Lloyd; Robert M Bryan; Ulf Simonsen; Ralf Köhler
Journal:  Basic Clin Pharmacol Toxicol       Date:  2013-06-27       Impact factor: 4.080

Review 10.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  11 in total

1.  The TWIK2 Potassium Efflux Channel in Macrophages Mediates NLRP3 Inflammasome-Induced Inflammation.

Authors:  Anke Di; Shiqin Xiong; Zhiming Ye; R K Subbarao Malireddi; Satoshi Kometani; Ming Zhong; Manish Mittal; Zhigang Hong; Thirumala-Devi Kanneganti; Jalees Rehman; Asrar B Malik
Journal:  Immunity       Date:  2018-06-26       Impact factor: 31.745

Review 2.  The family of K2P channels: salient structural and functional properties.

Authors:  Sylvain Feliciangeli; Frank C Chatelain; Delphine Bichet; Florian Lesage
Journal:  J Physiol       Date:  2015-01-22       Impact factor: 5.182

3.  TASK-1 potassium channel is not critically involved in mediating hypoxic pulmonary vasoconstriction of murine intra-pulmonary arteries.

Authors:  Ghulam Murtaza; Petra Mermer; Anna Goldenberg; Uwe Pfeil; Renate Paddenberg; Nobert Weissmann; Guenter Lochnit; Wolfgang Kummer
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 4.  Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?

Authors:  Mélanie Lambert; Véronique Capuano; Andrea Olschewski; Jessica Sabourin; Chandran Nagaraj; Barbara Girerd; Jason Weatherald; Marc Humbert; Fabrice Antigny
Journal:  Int J Mol Sci       Date:  2018-10-14       Impact factor: 5.923

Review 5.  Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.

Authors:  Hélène Le Ribeuz; Véronique Capuano; Barbara Girerd; Marc Humbert; David Montani; Fabrice Antigny
Journal:  Biomolecules       Date:  2020-09-01

Review 6.  Two-Pore-Domain Potassium (K2P-) Channels: Cardiac Expression Patterns and Disease-Specific Remodelling Processes.

Authors:  Felix Wiedmann; Norbert Frey; Constanze Schmidt
Journal:  Cells       Date:  2021-10-27       Impact factor: 6.600

7.  Recombinant tandem of pore-domains in a Weakly Inward rectifying K+ channel 2 (TWIK2) forms active lysosomal channels.

Authors:  Nicole Bobak; Sylvain Feliciangeli; Cheng-Chang Chen; Ismail Ben Soussia; Stefan Bittner; Sophie Pagnotta; Tobias Ruck; Martin Biel; Christian Wahl-Schott; Christian Grimm; Sven G Meuth; Florian Lesage
Journal:  Sci Rep       Date:  2017-04-05       Impact factor: 4.379

Review 8.  Clinical Importance of the Human Umbilical Artery Potassium Channels.

Authors:  Margarida Lorigo; Nelson Oliveira; Elisa Cairrao
Journal:  Cells       Date:  2020-08-25       Impact factor: 6.600

9.  Transcriptomic profile of cationic channels in human pulmonary arterial hypertension.

Authors:  Francisco Perez-Vizcaino; Angel Cogolludo; Gema Mondejar-Parreño
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

10.  Hemodynamic and Pathologic Characterization of the TASK-1-/- Mouse Does Not Demonstrate Pulmonary Hypertension.

Authors:  Melanie G Kitagawa; Julia O Reynolds; Xander H T Wehrens; Robert M Bryan; Lavannya M Pandit
Journal:  Front Med (Lausanne)       Date:  2017-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.